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Global  initiatives  such  as  the  Millennium  Development  Goals  have  led  to major  improvements  in the
health  of women  and children,  and  signiﬁcant  reductions  in  childhood  mortality.  Worldwide,  mater-
nal  mortality  has  decreased  by 45% and  under-ﬁve  mortality  has  fallen  by over  50%  over the  past  two
decades  [1].  However,  improvements  have  not  been  achieved  evenly  across  all  ages;  since  1990,  under-
ﬁve  mortality  has declined  by  ∼5%  annually,  but the  average  decrease  in neonatal  mortality  is  only  ∼3%
per  year.
Against this  background,  the  Bill  and  Melinda  Gates  Foundation  (BMGF)  convened  a  meeting  in Berlin on
January  29–30,  2015  of  global  health  stakeholders,  representing  funders,  academia,  regulatory  agencies,
non-governmental  organizations,  vaccine  manufacturers,  and  Ministries  of Health  from  Africa  and  Asia.
The topic  of  discussion  was  the  potential  of  maternal  immunization  (MI)  to achieve  further  improvements
in  under-ﬁve  morbidity  and  mortality  rates  in  children,  and  particularly  neonates  and  young  infants,
through  targeting  infectious  diseases  that are  not  preventable  by  other  interventions  in these  age  groups.
The  meeting  focused  on effective  and  appropriately  priced  MI  vaccines  against  inﬂuenza,  pertussis,  and
tetanus,  as well  as against  respiratory  syncytial  virus,  and  the  group  B Streptococcus,  for  which  no  licensed
vaccines  currently  exist.The  primary  goals  of  the BMGF  2015  convening  were  to bring  together  the  global stakeholders  in
vaccine  development,  policy  and  delivery  together  with  the  Maternal,  Newborn  and  Child  Health  (MNCH)
community,  to get  recognition  that  MI is  a strategy  shared  between  these  groups  and  so encourage
increased  collaboration,  and  obtain  alignment  on  the  next  steps  toward  achieving  a  signiﬁcant  health
impact  through  implementation  of a MI  program.
ublis©  2015  The  Authors.  P
. Introduction
Millennium Development Goal 4 targeted a decrease in under-
ve mortality by 2/3 between 1990 and 2015 [1]. Latest ﬁgures
how the rate has been halved from 1990 to 2012, representing
n annual decline of ∼5% per year (Fig. 1). However, the annual
ecline in neonatal mortality has only been ∼3% per year; neonatal
ortality now accounts for 44% of under-ﬁve mortality, and this
ay  increase to ∼55% by 2035 [2]. This makes neonates a major
∗ Corresponding author. Tel.: +1 2067267144.
E-mail address: ajoke.termeulen@gatesfoundation.org (A. Sobanjo-ter Meulen).
ttp://dx.doi.org/10.1016/j.vaccine.2015.08.047
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
target for future initiatives to achieve the Sustainable Development
Goals for 2030 currently under discussion.
Globally, more than half of the 2.76 million neonatal deaths
annually are associated with infections (22%) or pre-term births
(35%), and 10–50% of stillbirths are estimated to be a consequence
of maternal infections [3]. Much of the improvement in child health
has been achieved through targeted vaccinations in Extended Pro-
gram on Immunization (EPI). However, such programs cannot
protect the substantial vulnerable population of newborns and
young infants who  are too young to receive their own  routine
immunizations, e.g., pertussis vaccination from 6 to 8 weeks of age
fails to protect against the signiﬁcant disease burden in the ﬁrst
month of life [4]. Maternal immunization (MI) offers an innovative
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Global under-ﬁve (U5), infant and neonatal mortality rates (1990–2012).
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mFig. 2. How MI  could complem
pproach to improve the health of mother, fetus and infant and
ay  signiﬁcantly impact neonatal mortality. As MI  targets pregnant
omen for immunization, such an initiative can be integrated in the
ontinuum of care of Maternal, Newborn and Child Health (MNCH)
rograms to build upon their established interactions between
regnant women and antenatal health care providers (Fig. 2).
MI could potentially have substantial impact on both maternal
nd infant mortality for some diseases for which there already are,
r soon will be vaccines (e.g., inﬂuenza, tetanus, malaria, hepatitis
). Focus of the Bill and Melinda Gates Foundation (BMGF) 2015
onvening was  on the potential impact of MI  on ﬁve pathogens –
nﬂuenza, group B Streptococcus (GBS), pertussis, respiratory syn-
ytial virus (RSV) and tetanus – that are serious causes of neonatal
orbidity and mortality. The three main objectives of the meeting
ere (i) to identify the key challenges (and potential solutions) that
ould prevent MI  having a major impact on preventable neonatal
ortality due to these infectious diseases in low income (LIC) and
ow-middle income (LMIC) countries, (ii) the strategic priorities for
uccessful implementation of MI,  and (iii) how to ensure increased
ollaboration between the global stakeholders in the vaccine and
NCH communities to align on a path forward, with the goal of
reating a sustainable MI  platform to address the current unmet
eeds in maternal, neonatal and infant health.
Presentations and subsequent discussions in ﬁve categories
overed the issues surrounding maternal immunization – the
nvestment case, the current evidence base, regulatory and policy
ssues, market dynamics and funding, and implementation.
. Investment case
To kick-off the meeting the BMGF presented high-level cost-
ffectiveness modeling analyses of four of the ﬁve MI targeted
accines as these will be required to inform investments in MI.
etanus was excluded from the analyses as it is already being imple-
ented as a well-established maternal vaccination program withhe MNCH continuum of care.
favorable cost-effectiveness in many of the LIC/LMIC countries. The
main outcome from the current modeling analyses was to illus-
trate the paucity of data necessary for an MI investment case for
inﬂuenza, RSV, GBS, and pertussis, which could be seen as a call
to arms for the research that needs to be done at regional and
global levels. Better understanding of the diseases and the potential
impact of maternal vaccination on health outcomes in the mother
and the fetus, such as stillbirths and pre-term deliveries, as well
as longer term sequelae in newborns, are essential if any modeling
effort is to produce coherent results to guide future investment in
MI.
3. Evidence base
The current state of knowledge and the requirements for further
research to enhance the evidence base and establish some of the
key parameters for each pathogen, were discussed in detail in this
session.
3.1. Tetanus
The current status of the established Maternal and Neonatal
Tetanus Elimination (MNTE) program was  presented as an example
of lessons learned, to deﬁne the needs for better surveillance and
studies to assess impact for each of the other pathogens. In addition
to vaccinating pregnant women the four components of the MNTE
program include vaccination of women of reproductive age in high-
risk areas, clean delivery and cord care at birth by trained personnel,
and measures to improve surveillance to assess the improvements
in prevention and treatment of neonatal tetanus. Over 15 years, the
MNTE has resulted in elimination (to 1 in 1000 live births) of neona-
tal tetanus in 35 of the 59 involved countries, and in many regions
of other countries, with a decrease in neonatal tetanus deaths from
200,000 in 2000 to 49,000 in 2013 [5].
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Many of the lessons learned from the MNTE show the opera-
ional challenges faced by such a program, including the difﬁculties
n reaching the most vulnerable populations with regular services,
he reliance on campaigns and outreach services for delivery, and
ide variations in service provision and quality within the same
ountry. The success of MNTE has been achieved due to the strong
olitical commitment to the program, ensuring steady ﬁnancial
upport, and wherever possible, integration with other interven-
ions to overcome potential local hesitance based on perceived
ovelty. Through direct involvement with local communities it has
een possible to overcome local issues that could otherwise pre-
ent vaccination, including educating mothers on the beneﬁts for
heir unborn child as well as for themselves. The MNTE experience
lso shows that different delivery models need to be applied in
ifferent countries and regions. Furthermore, there is no universal
odel that is acceptable to all and these lessons learned will need
o be appropriately adapted to the speciﬁc vaccine target, as well
s the geographical context.
.2. Inﬂuenza
An estimated 28k–110k children died in 2008 due to inﬂuenza
nfection, 99% in LIC/LMIC [6], with the major burden of hospitaliza-
ions in the under-one age group for those not infected with HIV [7].
vidence from inﬂuenza pandemics shows that inﬂuenza infection
an cause signiﬁcant health issues in pregnant women, affecting
oth mother and fetus, potentially leading to pre-term births and
tillbirths [8]. However, there is little evidence to establish the risk
actors and level of complications resulting from seasonal inﬂuenza
nfection, making it difﬁcult to estimate the overall health impact,
specially at a country level. Although complicated by the rel-
tively high levels of HIV-infection, clinical trials in Africa have
roven the clinical efﬁcacy of inﬂuenza vaccination. Separate trials
ave conﬁrmed that MI  partially protects < 6 month-olds against
nﬂuenza illness with a vaccine effectiveness of 63% [95% CI: 5–85]
n Bangladesh [9] and vaccine efﬁcacy of 48.8% [95% CI: 11.6–70.4]
n South Africa [10]. Some data from high-income countries (HIC),
hich is predominantly from observational studies, has indicated
hat inﬂuenza MI  may  have a small but signiﬁcant effect on preterm
irth rates and small gestational size of the neonate [11], but lack of
ata may  lead to underestimation of the disease burden and poor
wareness in LIC countries.
More active surveillance of inﬂuenza is required in the African
nd South-East Asian regions to establish the local burden of severe
isease, together with effectiveness studies, particularly on HIV-
nfected mothers and HIV-exposed infants. The seasonal nature of
nﬂuenza disease and annual strain variations, which impose sig-
iﬁcant logistical problems in inﬂuenza vaccine design (to match
irculating strains) and delivery, make investment in the develop-
ent of a universal vaccine a high priority.
.3. Group B Streptococcus
Where data is available, GBS is the single most frequent
ause of neonatal sepsis and meningitis, with an estimated
lobal disease burden of 0.53 cases per 1000 live births [12];
0% of cases occur in the sub-Saharan African region, with low
ncidence in the few reports from the Asian region. Most cur-
ent health burden data comes from developed countries such
s the US, where GBS remains the most frequent cause of
eonatal sepsis and meningitis [13], despite the introduction of
creening of mothers at risk and intrapartum antibiotic prophy-
axis (IAP) to prevent early onset disease (EOD). IAP has led
o a >80% reduction of EOD, however, the effectiveness of thiscine 33 (2015) 6388–6395
strategy appears to have plateaued and, as anticipated, had no
impact on late-onset disease. US incidence remains at ∼0.25
cases per 1000 live births, with 50% of cases in full-term infants;
symptoms include sepsis (85%), pneumonia (20%) and meningi-
tis (5%), and the mortality rate is 3–7% [14]. Survivors can have
signiﬁcant long-term sequelae [15], which, if prevented through
vaccination, could have a major impact on cost-effectiveness of the
vaccine.
Maternal antibodies are protective against early onset GBS dis-
ease [16,17], so MI  vaccines against the most prevalent serotypes
(Ia, Ib, II, III, IV and VI) are expected to provide broad coverage. A
vaccine candidate against serotypes Ia, Ib and III, covering ∼79%
of circulating strains [12], was  shown to be well-tolerated and
immunogenic against all three serotypes in non-pregnant women.
Further epidemiologic data in LIC, including laboratory conﬁr-
mation of sepsis with serotype identiﬁcation, will allow targeting
of the most important serotypes responsible for early and late onset
GBS disease in multivalent vaccines. However, while initial devel-
opment, funding and licensure of such vaccines will probably use
systems already in place in HIC, this will have to be in partnership
with LMIC, as efﬁcacy trials will be prohibitively expensive in HIC
due to the low burden of disease.
3.4. Pertussis
The greatest mortality burden of pertussis in developed and
developing countries is in very young infants, despite the introduc-
tion of pertussis-containing vaccines in the EPI schedule. Waning
vaccine-induced immunity leads to circulation of the pathogen
in older subjects, including parents and siblings, who can then
infect vulnerable neonates before they are old enough to be vac-
cinated. In the US, pertussis-related deaths mainly occur in 0–3
month-olds [18]. Globally, the number of pertussis deaths in under-
ﬁves is believed to be ∼60,000 per year [19], but may be much
higher as documented cases are thought to only represent 1–2%
of actual cases. Clinical diagnosis is difﬁcult as infants do not dis-
play the characteristic whooping cough. Pneumonia, a frequent
complication, is often cited as the cause of death where conﬁr-
mation of pertussis infection by PCR or culture is not available
[20]. This makes currently available data from LIC/LMIC particularly
unreliable, and severe underreporting is highly likely. Maternal
immunization against pertussis in the third trimester has been
shown to be safe for mother and fetus [21], and is recommended
in the US [22] and Argentina [23] as a reduced dose diphtheria,
tetanus, acellular pertussis (Tdap), and in the UK as Tdap-IPV [24].
Vaccine effectiveness in the UK has been shown to be 90% (95%
CI: 82–95) in infants up to 3 months of age born to mothers who
received Tdap-IPV [25]. In a smaller case–control study of mater-
nally administered Tdap-IPV, the same group recently conﬁrmed a
vaccine effectiveness of 93% (95% CI: 81–97) in infants < 8 weeks-
old, conﬁrming that the drop in cases was  not due to improved
diagnostics, nor the seasonal nature of pertussis infections [26].
Such data have led to the SAGE recommendation to vaccinate
pregnant women with a dose of vaccine containing acellular per-
tussis in the 2nd or 3rd trimester [27], which is expected to be
endorsed soon by the WHO  for those countries seeing an increase
in infant pertussis incidence.
Implementing maternal pertussis immunization needs to be
informed by more active surveillance studies to assess actual
disease incidence in infants and children, with laboratory con-
ﬁrmation. There also needs to be an assessment of the potential
interference of pertussis MI  with subsequent infant DTwP vac-
cinations in the EPI. A major challenge will be the cost of
pertussis vaccines suitable for use in pregnant women in LIC/LMIC,
requiring an alternative to the Tdap or Tdap-IPV currently used
in HIC.
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.5. RSV
There is a high incidence of RSV infection in infants and chil-
ren, responsible for ∼22% of all severe Acute Lower Respiratory
nfection (ALRI) cases, and accounting for over 33 million cases
f RSV-ALRI in under-ﬁves in 2008, with most occurring before 6
onths of age. RSV was estimated to cause ∼66k–199k deaths in
nder-ﬁves in 2008 [28] and ∼23k–66k deaths in 2013 [29]. There
s ongoing debate whether RSV in early childhood leaves survivors
ith signiﬁcant sequelae, including wheezing and asthma, in later
ife, but if this were the case it would have a substantial impact on
ost-effectiveness calculations.
Levels of maternal antibodies against RSV in infants have been
hown to inversely correlate with the risk of RSV-hospitalization
30], and multiple doses of a monoclonal antibody (palivizumab)
ave also been shown to be effective in decreasing hospitalizations
n premature infants with RSV [31]. This therapeutic approach may
ead to availability in LIC/LMIC if low cost versions can be produced,
ut MI  remains as an attractive solution if protection is durable in
he infant, and may  lead to a combination approach to maximize
rotection. One candidate MI  vaccine based on the RSV F protein is
n phase II clinical development trials [32], but efﬁcacy in protecting
regnant women and infants needs to be assessed.
Data from ongoing and future studies are necessary to fully
issect the role of RSV in ALRI, and the global and regional dis-
ase burdens, particularly in pregnancy, and long-term sequelae.
lthough RSV is a seasonal disease in most developing countries,
verlapping with inﬂuenza during the winter, in the more temper-
te climates of many LIC/LMIC it is present all year round, although
till with some seasonal peaks, so the health burden impact may  be
nderestimated. More active surveillance is required, particularly
n Asia, for baseline epidemiology, as well as long-term follow up
f those women involved in clinical trials of vaccine candidates.
. Regulatory
This session addressed the challenges developers and regula-
ory authorities face in addressing safety, efﬁcacy, labeling and
egulatory pathways for MI  vaccines. Regulators face safety and
fﬁcacy considerations for all three groups of vulnerable subjects,
he pregnant woman, the fetus, and the newborn infant affected by
I  [33]; consideration needs to be made to have all three covered
n the label (Fig. 3).
MI  vaccines for use in LIC/LMIC may  be approved in Europe using
he Article 58 regulatory pathway, or in the US through the investi-
ational new drug (IND) program. Inﬂuenza, tetanus, and pertussis
accines are already used in pregnant women without speciﬁc label
ndications, but new vaccines for GBS, RSV and potentially pertus-
is, may  require labeling that reﬂects their speciﬁc indication as MI
accines. The FDA is currently considering the speciﬁc clinical trial
equirements for MI,  as it requires “substantial evidence of effec-
iveness” for any label indications, including pregnant women  as
art of the Pregnancy and Lactation Labeling Rule (PLLR). In addi-
ion, as many MI  clinical trials will be undertaken in LIC/LMIC, it
ill be essential that discussions about regulatory requirements
or clinical trials and registration are also undertaken with relevant
eveloping country regulators, e.g., the South African Medicines
ontrol Council, and manufacturers should also open discussions
ith regional or national regulatory bodies such as the African
accine Regulatory Forum. They should be engaging in discussions
ith regulators early in the development process to determine the
abel requirements to support the MI  indication and the recom-
endation for use in pregnant women, to ensure the appropriate
linical trials are performed.cine 33 (2015) 6388–6395 6391
Successful licensure in the EU or US must be followed by WHO
prequaliﬁcation before registration in the countries where they will
be used. WHO  prequaliﬁcation, which may  take more than a year,
is a required assessment for UN purchasing agencies of the quality,
efﬁcacy and safety of a vaccine, and is also used by countries whose
regulatory authorities are not yet able to evaluate new vaccines for
registration purposes. Prequaliﬁcation is therefore essential for the
implementation of MI  in many LIC/LMIC. As epidemiologic con-
ditions in high-income countries (HIC) may  differ from those of
the target countries, the WHO  also assesses whether any local dif-
ferences in LIC/LMIC are liable to affect safety or effectiveness. To
facilitate ﬁnal registration, discussion with the National Regulatory
Authority (NRA) in the target country/region should begin while a
vaccine is still in the development stage in Europe or the US.
Most LIC/LMIC with institutions with the capacity to implement
vaccine trials now have national or institutional research ethics
committees/IRBs and appropriate approval must be sought from
these committees. Clinical trials conducted in LIC/LMIC, whether
for US, European or NRA approval, or WHO  prequaliﬁcation, must
satisfy stringent ethical standards. Most vaccines being evaluated in
a clinical trial will not have a registered indication to support their
use for MI.  In this case the woman  must be informed about what
is already known about vaccine safety in pregnancy, and about the
potential risks and beneﬁts of the use of the vaccine in pregnancy.
If the control group is receiving “less than the best current proven
standard of care available globally”, as required by the Helsinki
Declaration, this may  be justiﬁed by the access to the best locally
available treatment augmented by improved healthcare that is pro-
vided to the pregnant women  through participating in the trial.
Local knowledge of population background rates of pregnancy
and birth outcomes is essential to monitor safety outcomes, birth
outcomes and perinatal and postnatal adverse events in order to
adequately assess the beneﬁt/risk proﬁle of the vaccine. Similarly,
efﬁcacy evaluations based on the desired indication require accu-
rate background rates of infection to calculate sample sizes for trials
necessary to achieve deﬁned end-points. If different manufactur-
ers are developing similar products, agreement should be sought
to deﬁne common end-points.
5. Policy
The matrix of policy-makers making decisions on vaccines and
MNCH at a global and country level, shown in Fig. 4, illustrates
the complexity of translating global policy to country level imple-
mentation, and highlights the need for coordination amongst all
involved to ensure cohesive MI  policy. This session was intended
to explain this to stakeholders in both groups to come to a common
understanding for the creation of policies for MI  at global, regional,
and national levels.
Vaccine-related policies from SAGE are used by WHO  member
states to assist in formulating policies about new vaccine introduc-
tion. The WHO’s regional Technical Advisory Groups (TAGs) then
further develop the SAGE recommendations to make them suitable
for the regional context. For the 75 countries that have functioning
National Immunization Technical Advisory Groups (NITAGs), con-
sideration should be given to adding reproductive health expertise
to the NITAG membership, to ensure comprehensive discussions
about MI  introduction. Clear data on local or regional disease bur-
den and potential cost beneﬁts need to be made available to inform
Ministries of Health and NITAGs’ decision-making processes.
Since 2002, WHO  Antenatal Care (ANC) guidelines have guided
the introduction of new interventions to promote the common
goals of improved healthcare, disease prevention and awareness
of potential complications. Delegates agreed that MI  must be inte-
grated within the current ANC platform, which itself is of variable
6392 A. Sobanjo-ter Meulen et al. / Vaccine 33 (2015) 6388–6395
Fig. 3. Regulatory pathways in LIC/LMIC and current vaccine status. (1) Lower middle income countries/lower income countries. (2) EMA  Article 58 program which allows
EMA  to issue a scientiﬁc opinion for medicines not intended to be used in the EU. (3) Pertussis Toxoid (PT). (4) Three valent (3-V).
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uality and effectiveness, with low coverage in many regions. Care-
ul assessment and planning must be made to ensure that the
uality of current ANC provisions does not decline because of the
dditional work required by MI.  Evidence of the further beneﬁts of
I  must be provided to the MNCH community to support MI  intro-
uction in ANC. Efforts must be made to create efﬁciencies with
ther ANC services including TT delivery, as in many settings it is
nlikely that additional human resources will be made available for
I.  The WHO  has promoted focused ANC, and is currently updating
he guidelines; a report is expected late in 2015. This may  repre-
ent an opportunity to integrate MNCH and vaccination policies,
ncluding MI  in SAGE and MNCH recommendations.
Another important consideration for countries is the ﬁnancial
mpact of changes in policy. Ministers of Health and NITAGs need to
e kept aware of imminent global recommendations and how these
ill translate into local policies in the immediate, intermediate and
ong-term so they can include costs of supply and distribution in
udget planning. This may  also trigger discussion at the national
evel of cost-effectiveness and cost-beneﬁts, in which NITAGs will
lay an important role to prioritize “affordable” options. There are
ommon challenges in all LIC/LMIC, such as the need to improve
uality and access to healthcare and enhance equity in health care
ervices.
. Market dynamics
Vaccine manufacturers were invited to present supply-side
hallenges they face in providing the necessary vaccines for the
roposed MI  programs, as they must be able to provide the
olumes necessary at prices deemed affordable by the funders of
uch programs.
The pharmaceutical industry typically invests in products
hat will be used in HIC, with development in established
esearch networks. Developing for LIC/LMIC involves additionaln Immunization. (2) Reproductive health/maternal, newborn, child and adolescent
costs – conducting trials in LIC/LMIC necessitates creating the
research infrastructure, recruitment of local staff, and dealing with
complex local regulatory processes. In the early phase of devel-
opment manufacturers are faced with uncertainties of current
demand and disease evolution due to lack of data on global dis-
ease burden, which may  impact future demand. This also affects
the market-demand modeling companies perform to justify their
investment, as data for such models is usually obtained from HIC.
To be conﬁdent that they are investing in the appropriate products,
companies must be involved in discussions of disease burden data,
surveillance to improve local knowledge of the pathogens and their
potential evolution.
A balance must be found between companies looking for higher
short-term pricing of a new product to ensure return on their
investment, and purchasers who have an interest in lower prices
in return for commitment to long-term contracts that include
purchasing of substantial quantities of vaccines, with assurances
on long-term sustainable ﬁnancing being available. One option
is to de-risk development costs of new MI  vaccines through
public–private partnerships, with organizations such as PATH and
BMGF.
As previously noted, pregnancy recommendations are often
issued for products that were initially not speciﬁcally indicated
for use in pregnant women. The high potential liability costs of
vaccinating pregnant women  has historically discouraged manu-
facturers from investing in MI  indications. Manufacturers need a
clear understanding of the risk/beneﬁt proﬁle, as well as robust
background data on the normal rates of adverse pregnancy out-
comes, to adequately address potential liability. This knowledge
will also enable independent Ethical Committees to fully assess
and contextualize potential vaccine-associated safety events in a
particular population and setting. Such efforts are further sup-
ported by the standardization of AEFI in pregnancy currently being
undertaken by the Brighton Collaboration.
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Market shaping will depend not only on licensure and rec-
mmendations from global bodies, but also on demand amongst
regnant women themselves, when they accept such vaccinations
re beneﬁcial to themselves and their unborn child. This will only be
chieved through education of women and healthcare providers on
he preventable disease morbidity and mortality burdens, and the
isk–beneﬁt proﬁle of the vaccine. Until safe, effective, and afford-
ble maternal vaccines become available to these populations, the
arket shaping process needs to be approached gradually by both
he vaccine and MNCH communities. Pilot studies to evaluate the
cceptability of MI  among pregnant women and providers, using
xisting vaccines such as inﬂuenza or pertussis, should be consid-
red to get an indication of program acceptability.
. Funding
This session explored the funding of healthcare initiatives in
IC/LMIC. Currently, funding is a mixture of private ﬁnance and
ational spending. GAVI, the most important non-governmental
onor for vaccines, is responsible for dispersal of ﬁnancing from
ultiple sources and accountable for ∼85% of the expected expen-
iture of $11 billion on vaccines from 2016 to 2020. This represents
 more coordinated scenario than for MNCH interventions, which
re funded primarily by national (∼$50 billion in 2010) rather than
rivate donors (∼$6.5 billion in 2010). If MI  is to be integrated
n MNCH programs, it will require bridge-building between the
wo funding groups to share the costs. Another issue relates to the
tructure of GAVI funding, which is based on agreed 5-year plans
the most recent of which was approved during the course of the
onvening!).
As with commercial use of vaccines, MI  will require mar-
et shaping for funders, who need to be reassured that MI  is
 cost-effective intervention that will provide a return on their
nvestment, mainly in terms of lower rates of mortality, and to a
esser extent morbidity, in women and their infants. Market shap-
ng will rely on provisioning the evidence base for the medical need,
nd the beneﬁts and cost-effectiveness through modeling, which
ay  be challenging where data is scarce or non-existent. In LIC and
MIC, funding channels need to be aware of the key mortality out-
omes and the potential of MI  against this background. In middle
ncome countries (MIC) where an increased proportion of funding
s domestic, the funding decision-making approach may  need to be
ifferent and the value of MI  a more attractive proposition.
The ﬁve-year GAVI funding cycle, during which new vaccines
re reviewed using relatively small datasets including phase IIb/III
ata and ideally efﬁcacy data, offers an opportunity to provide such
ata, but does imply a ﬁve-year delay. However, it may  be possible
o work with GAVI to determine supply requirements and already
nclude MI  as part of future investments.
. Implementation
This session looked at the barriers and opportunities to imple-
entation of MI  as an integrated part of ANC, and the strategy to
ove forward to ensure demand, vaccine supply and monitoring
f the impact of MI.
The ﬁrst barrier is vaccine acceptance by pregnant women.
nfectious diseases are known to be killers of infants, and the
omen in LIC communities will accept that they and their chil-
ren are vaccinated to protect them against such diseases when
hey see the evidence for prevention of morbidity and mortality
n their own  communities; the success of the maternal tetanus
accination program is evidence of this. While a communication
trategy is necessary to educate future mothers of the beneﬁts of
I to themselves and their fetus and infant, community ownershipcine 33 (2015) 6388–6395 6393
in LIC is key to securing conﬁdence in the beneﬁts of MI  to ensure
that it will endure. In many cases family members, tribal elders and
religious leaders critically inﬂuence community acceptance of new
initiatives, so education on MI  must include the whole community.
For successful integration of MI  with ANC, doctors and midwives
currently providing healthcare support to many pregnant women
are a key group who  must be convinced of the need for and ben-
eﬁts of MI.  They must also be reassured that the extra workload
will receive additional support, with funding of more healthcare
personnel as part of the MI  package, so it will not interfere with
their core duties (unless combination vaccines become available).
For both ANC and MI  to be successful midwives should be allowed
to primarily focus on their skills of basic midwifery; it is not nec-
essary that the recommender and vaccinator are the same person.
One possibility is the provision of adequately trained additional
“vaccination” personnel to allow synergistic care with midwives
currently supporting ANC, whose one-to-one interaction with the
pregnant woman  is key in ensuring the MI  intervention is accepted,
but this is unlikely to be possible in many settings. Another possible
avenue is collocating MI  with the EPI care offered to both mother
and newborn, which may  allow their integration. Schedules must
be further reviewed as ANC and vaccination visits may  not coincide,
which would be a potential barrier to coverage.
Once MI  programs are implemented, safety and efﬁcacy assess-
ments will be vital to ensure continuing support. Efﬁcacy data
will lead to evidence-based demand, but will initially be com-
promised by the lack of baseline data. Health Ministers will be
able to use local effectiveness data to ensure ongoing funding, and
to support local communication efforts to maintain and improve
acceptance, coverage and uptake. Such information can be made
available to the local healthcare provider who can communi-
cate with the communities in culturally appropriate language.
Although active vaccine safety surveillance is the gold standard,
programs often need to rely on passive surveillance, which may
fail when it relies on anecdotal data. Preference must be for
active surveillance with community support. PAHO may provide
lessons learned in this area as they are moving from passive to
active surveillance. Other experience relevant to the implementa-
tion of MI  programs may  be provided by PMTCT programs, and
from the successful experience of MNTE in the target countries
themselves.
9. Summary
The Berlin convening brought together key stakeholders in
maternal, newborn and infant health from the MNCH and vaccine
communities to discuss the potential for MI  to address the cur-
rent context of general reductions of morbidity and mortality in
under-ﬁves, but less success in reducing the mortality burden in
neonates. It was  generally agreed that MI  is an attractive approach
to address a disease burden due to different pathogens affecting
mothers, neonates and infants, that is currently not addressed by
other interventions, and that will grow proportionately with time.
As noted in the key takeaways from the different sessions (Table 1),
the common theme arising from the convening discussions was
the current shortage of robust data on disease burden in LIC and
LMIC, including important factors such as numbers of stillbirths
and preterm births, and their causality, as well as other pregnancy
and birth complications caused by the pathogens targeted by MI.
This baseline data is needed for accurate calculation of the cost-
beneﬁts of MI  programs to secure ﬁnancial and policy support for
MI,  and stimulate manufacturer investment in new vaccine devel-
opment. Paradoxically, those populations with the highest disease
burden, neonates and very young infants, suffer from the poorest
quality data.
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Table 1
Key takeaways from the different discussions.
Evidence base
• All the targeted pathogens suffer from a relative lack of disease burden data in LIC/LMIC, especially in neonates and young infants, who have the highest predicted
disease burden.
• Data is needed on disease incidence in these age groups, together with studies on birth outcomes, fetal health and hospitalization rates in LIC/LMIC.
•  This will require development and implementation of affordable diagnostic tools and guidelines for their application in neonatal illnesses.
•  MI  programs will only be successful if affordable vaccines are made available – there are currently no licensed vaccines against GBS or RSV, nor a low-cost acellular
pertussis maternal vaccine option.
Regulatory
• Developers of new vaccines for MI  must engage early with regulators (national NRAs, EU or US), and with local experts to design trials to ensure realistic end-points
for  safety and efﬁcacy assessments are used that will support the MI indication on the label.
•  Such end-points must be based on accurate measures of disease burden.
•  Clinical trials must be performed to the same high ethical standards, in HIC or LIC, with clear communication of risks and beneﬁts to participants.
•  WHO  prequaliﬁcation after national NRA, EU or US approval may take a year, although efforts are being made to expedite this process.
•  For licensed vaccines, MI  may  be added as an indication when sufﬁcient data from clinical trials in pregnant women shows safety and efﬁcacy in both mother and
the  newborn, and manufacturers should be willing to update their label when such data becomes available.
Policy
•  The key policy challenge for MI  is to have global recommendations that are taken up at the national level, with buy-in from political leadership, media, lay and
religious communities and the experts in NITAGs and regional TAGs.
• This requires enhancement of the current evidence base at country and regional levels, with emphasis that MI  is a synergistic intervention for current ANC and
MNCH platforms to enhance the health of women and children, with a favorable risk/beneﬁt balance.
•  The ﬁnancial aspect must also be considered, with open discussion on potential cost-effectiveness, budget requirements and sustainable ﬁnancing.
Market  dynamics
• Manufacturers suffer from the lack of background disease burden data from targeted LIC, and particularly the evidence base to support safety and efﬁcacy
calculations to justify vaccine development. Such data is necessary for the investment planning that is required for development of new products, with unknown
uptake  and ﬁnancing.
• The complexity of regulatory pathways for pregnant women, with concerns about ethics and liability, may  also de-incentivize future development.
•  Public-private partnerships may  overcome some of these issues, but partnership between industry and the global health community are also necessary to
encourage future investment and development.
Funding
• Decisions to invest in MI need to be informed from a robust evidence base, particularly inﬂuenced by data on mortality, although serious morbidity rates cannot be
ignored in LIC/LMIC.
• Country-level funding will be essential to supplement ﬁnancing from vaccine and MNCH donors, but priorities will vary from country to country, which will affect
decisions to support MI  locally.
• Simple ﬁnancing mechanisms, combining funding from global and country-level sources, will be necessary to ensure integration of MI  with ANC to minimize
complexity and maximize impact.
Implementation
• Patient acceptance of MI will require trust engendered by educating the community, including local leadership, on the beneﬁts and risks of vaccination and of the
diseases  themselves.
• Workload of the healthcare providers already implementing ANC must be considered when adding the additional responsibility of MI,  with adequate resources
provided.
•  Synergies with existing interventions such as TT, as well as other aspects of ANC and EPI need to be sought.
•  Sustained acceptance will require active monitoring of the safety and impact of MI,  with ongoing community education to support uptake, quality of care and
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multimately ﬁnancing when beneﬁts are shown to be cost-effective.
To strengthen the evidence base in LIC/LMIC requires an initial
nvestment in surveillance and research, using new diagnostic tools
nd guidelines, especially in those regions where the data is the
eakest but the impact is likely to be the highest. Such research
ust also examine the impact on maternal and fetal health, birth
utcomes, long term sequelae, disease severity, and hospitalization
ates. Establishing clinical research to assess background disease
ates, through early engagement of NRAs from LIC/LMIC, may  also
elp create the research platforms on which to build appropriate
afety monitoring of clinical vaccine trials in pregnant women  in
he targeted countries.
Although successful implementation of MI  programs will be
ore sustainable if it is integrated with currently established ANC
nitiatives, it was recognized that regional and national variations
n ANC provision mean that a “one-size-ﬁts-all” approach will not
ork. MI  programs will have to be planned on a country-by-country
asis, with clear evidence of the local beneﬁts for both mother and
hild. Acceptance by healthcare providers who will implement MI
ill require capacity building through ﬁnancial and logistical sup-
ort for integration with related programs, together with strong
lobal recommendations (WHO SAGE) to ensure uptake of MI  pro-
rams at the regional and country levels. Broad acceptance will also
e dependent on regional and local communication through WHO
egional TAGs, Ministries of Health and NITAGs, and lay groups
uch as tribal and religious leadership, of the safety and beneﬁts of
aternal vaccination.10. Conclusion
MI  has a future potential to contribute to the reduction of mater-
nal, neonatal and infant mortality, as well as to improve maternal
and child health and prevent stillbirths. The critical factors to
ensure success of MI  will be early inclusion of all stakeholders
in discussion of the development of new vaccines and the imple-
mentation of MI  vaccination programs. Such discussions must be
informed by research into disease burdens in the targeted countries
or regions, creating clear beneﬁt/risk proﬁles for vaccination that
weigh the consequences of infection with possible vaccine adverse
events. Early engagement of global organizations who  support
licensure and funding of MI  vaccines, with manufacturers and
health authorities, and those already involved in health initiatives
for pregnant women and their infants will establish a common goal
for all stakeholders.
With WHO  approval and support, successful collaboration
between funders and pharmaceutical companies developing the
necessary new vaccines, and the establishment of adequate surveil-
lance networks to perform the required local assessments of
baseline data to provide the evidence to all stakeholders, MI
may signiﬁcantly decrease the disease burden in age groups that
other healthcare initiatives cannot address. Collaboration and
coordination between the various stakeholders in maternal and
infant health, to integrate MI  with antenatal care programs, may
prevent a signiﬁcant proportion of the infections and consequent
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orbidity and mortality in pregnant women and their children,
efore and after birth, that are not currently addressed by estab-
ished health initiatives.
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